An American Journal of Managed Care® Symposium: Examining Treatment Advancements in Psoriasis and Psoriatic Arthritis

New data presented at the 2025 World Congress of Pediatric Dermatology annual meeting highlights the efficacy and safety of once-daily icotrokinra (JNJ-2113) in adolescents with moderate to severe plaque psoriasis.

August is National Psoriasis Awareness Month, and on this episode of Managed Care Cast, we bring you an excerpt of an interview with a New Jersey dermatologist about the changing concept of psoriasis as more than just a skin disease.

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found tildrakizumab outcomes to have a mean drug survival of almost 3 years.

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found bimekizumab to have benefits beyond safety and efficacy findings.

Biologics targeting interleukin (IL)-12, IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting highlighted the importance of improving quality of life in patients with moderate to severe scalp psoriasis.